What is the difference between MCAS, mastocytosis and allergies?
These conditions can involve mast cells, but their mechanisms and diagnostic criteria differ, and they can coexist.
- 8 sources
- 4 min read
- Clinical review
- Verified 9 November 2026
Key points
- Mastocytosis is a hematologic neoplasm (a proliferation of mast cells derived from a single abnormal cell) characterized by the expansion and accumulation of abnormal (clonal) mast cells in tissues; it can be cutaneous or systemic [1, 2].
- MCAS is a systemic activation syndrome that meets clinical, laboratory and treatment-response criteria; it can be primary (clonal), secondary or idiopathic [3, 4].
- An IgE-mediated allergy can activate mast cells and cause an acute reaction; this does not automatically mean that the person has MCAS. An allergy can, however, be the cause of secondary MCAS when the full criteria are met [3, 4].
- Mastocytosis, allergy and hereditary alpha-tryptasemia can coexist; the criteria and tests used to tell them apart are not interchangeable [4, 5].
Mastocytosis: clonal expansion and accumulation
MCAS: systemic activation, with or without mastocytosis
Allergy: mast cell activation that is often IgE-dependent
In an emergency. If you have trouble breathing, throat swelling or feel faint after an exposure, call 911 (or your local emergency number); never delay emergency care for a blood test.
Comparison table
| Entity | Main mechanism | What supports it | What is not enough |
|---|---|---|---|
| Mastocytosis | Clonal expansion and accumulation of mast cells | Histology, morphology, immunophenotype, KIT and classification criteria | Flushing, itching, an isolated high baseline tryptase |
| IgE-mediated allergy | IgE sensitization followed by activation on exposure | A consistent exposure history, allergy tests suited to the context | An undocumented reaction or an isolated chronic symptom |
| MCAS (ECNM-AIM) | Recurrent systemic episodes of mast cell activation | Three criteria that must all be met: clinical, biochemical, treatment response | An isolated response to an antihistamine or nonspecific symptoms |
The situation in France
References and level of evidence
- Valent P, Akin C, Hartmann K, et al. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. HemaSphere, 5(11):e646 2021. DOI: 10.1097/HS9.0000000000000646. PMID: 34901755.(guideline or consensus)Limitations: Consensus proposal from European and American experts (August 2020 conference); classifications have changed since, and any detailed presentation must state which edition is cited. Read: full text (PMC8659997).Declared conflicts of interest: Several authors declare consulting activities, fees or funding (including Novartis, Deciphera, Blueprint Medicines); the others declare none
- French mastocytosis reference center (CEREMAST), MaRIH rare-disease network; coordinated by Dr Cristina Livideanu. Mastocytoses non-avancées chez l'adulte — Protocole national de diagnostic et de soins (PNDS). French national diagnosis and care protocol (PNDS), June 2022 (published on the website of the French National Authority for Health, HAS) 2022.(guideline or consensus)Limitations: Covers non-advanced mastocytosis in adults; it is not a stand-alone PNDS devoted to isolated MCAS. Read: table of contents, scope and selected passages.Declared conflicts of interest: Not reviewed in the part of the source that was read
- Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol, 157(3):215–225 2012. DOI: 10.1159/000328760. PMID: 22041891.(guideline or consensus)Limitations: Consensus proposal from an expert conference (2010), refined by later updates; not a population study. Read: full text (PMC3224511).Declared conflicts of interest: No declaration found in the text that was read
- Valent P, Hartmann K, Bonadonna P, Niedoszytko M, Triggiani M, Arock M, Brockow K. Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022. Int Arch Allergy Immunol, 183(7):693–705 2022. DOI: 10.1159/000524532. PMID: 35605594.(guideline or consensus)Limitations: Expert synthesis (Collegium Internationale Allergologicum), not a meta-analysis. Read: full text (PMC9393812).Declared conflicts of interest: Several authors declare consulting activities, fees or research funding (including Novartis, Blueprint, Deciphera, Thermo Fisher); P. Valent funded by the Austrian Science Fund (FWF)
- Glover SC, Carter MC, Korošec P, Bonadonna P, Schwartz LB, Milner JD, Caughey GH, Metcalfe DD, Lyons JJ. Clinical relevance of inherited genetic differences in human tryptases: Hereditary alpha-tryptasemia and beyond. Ann Allergy Asthma Immunol, 127(6):638–647 2021. DOI: 10.1016/j.anai.2021.08.009. PMID: 34400315.(evidence synthesis)Limitations: Literature review; prevalence estimated mainly in white populations. Read: full text (author manuscript PMC9413800).Declared conflicts of interest: Not reviewed in the part of the source that was read
- Lee E, Picard M. Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach. Allergy Asthma Clin Immunol, 21(1):49 2025. DOI: 10.1186/s13223-025-00998-9. PMID: 41272881.(evidence synthesis)Limitations: Practical narrative review based on the ECNM-AIM criteria, adapted to the Canadian setting; test availability varies by country. Read: full text (PMC12639879).Declared conflicts of interest: M. Picard: fees from Novartis, Sanofi, Lundbeck and Celltrion unrelated to this work, associate editor of the journal, investigator in a study funded by Telios; E. Lee: none
- Valent P, Bonadonna P, Hartmann K, et al. Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. Int Arch Allergy Immunol, 180(1):44–51 2019. DOI: 10.1159/000501079. PMID: 31256161.(evidence synthesis)Limitations: Focused narrative review written by the group that devised the formula; not an original validation study. Read: full text (author manuscript PMC7115850).Declared conflicts of interest: Several authors declare research funding, consulting or fees (including Deciphera, Novartis, Blueprint, Thermo Fisher/Phadia); others declare none
- French mastocytosis reference center (CEREMAST), MaRIH rare-disease network. Mastocytoses avancées de l'adulte — PNDS. HAS (French National Authority for Health), institutional web page, posted July 17, 2025 2025.(guideline or consensus)Limitations: Scope limited to advanced mastocytosis; HAS states that it has not validated this PNDS. Read: HAS presentation page (PNDS document not read).Declared conflicts of interest: Not reviewed in the part of the source that was read